C2 Therapeutics Announces Initiation of Coldplay III Trial Validating the C2 CryoBalloon™ Focal Ablation System

Posted by Ellie Martinez on Jun 07, 2016

REDWOOD CITY, Calif.--C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system.

 

Data from Four Studies Reinforcing the Safety and Efficacy of the C2 CryoBalloon

Posted by Ellie Martinez on May 24, 2016

REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016,which is taking place May 21 – 24 in San Diego.

 

Read full release here. 

C2 Therapeutics Announces Leadership Team Expansion

Posted by Peter Garcia-Meza on Jan 25, 2016

REDWOOD CITY, Calif. – January 26, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced the appointment of five new members to its leadership team. These individuals join an existing team of seasoned leaders who will be instrumental in enabling C2 Therapeutics’ continued development and growth.

Click here to see full release.

C2 Therapeutics receives 510(k)

Posted by Peter Garcia-Meza on Jul 27, 2015

Redwood City, Calif.July 29, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of unwanted tissue in the esophagus, today announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System.

“The clearance of Coldplay Cryoballoon Full and Swipe Systems is an important milestone in broadening the company’s portfolio,” said Peter Garcia-Meza, President and CEO of C2 Therapeutics. “The Full and Swipe Ablation Systems will be critical in allowing physicians to ablate larger areas of tissue in endoscopic applications.”

 

Successful Safety and Dosing Results Published

Posted by Peter Garcia-Meza on Jul 20, 2015

Redwood City, Calif.July 20, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced the publication of excellent safety and dosing data related to the company’s Coldplay Cryoballoon™ Focal Ablation System.  Results from the prospective, non-randomized study titled, “Treatment of Barrett’s Esophagus with a novel focal cryoablation device: a safety and feasibility study” were published in the latest edition of the scientific journal Endoscopy.

Click here to see full release.

US ONLY: The Coldplay CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s Esophagus with high grade dysplasia.

 

EU ONLY: The CryoBalloon Focal Ablation System is used to ablate unwanted tissue in the gastrointestinal tract, including treatment of Barrett’s Esophagus and squamous dysplasia, by application of extreme cold.

C2 Therapeutics

303 Convention Way
Suite 1
Redwood City, CA 94063
(866) 515-3861